Becton, Dickinson & Co. (BDX) Dividend Details and dates on New York Stock Exchange

Becton, Dickinson & Co. Dividend Stock Review

New York Stock Exchange

Becton, Dickinson & Co. (BDX) Dividend Details and dates on New York Stock Exchange

Becton, Dickinson & Co. Becton, Dickinson & Co. is a global medical technology company. The company is engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The company operates through two worldwide business segments: BD Medical and BD Life Sciences. The BD Medical segment produces medical devices that are used in healthcare settings. This segment product includes needles, syringes and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles for the self-injection of insulin and other drugs used in the treatment of diabetes. The BD Life Sciences segment produces products for the safe collection and transport of diagnostic specimens, as well as instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. The segment also produces research and clinical tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes. The principal products and services in the Life Sciences segment include integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood culturing and tuberculosis culturing systems; molecular testing systems for infectious diseases and women's health; microorganism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; microbiology laboratory automation; plated media; fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; molecular indexing and next-generation sequencing sample preparation for genomics research; clinical oncology, immunology and transplantation diagnostic/monitoring reagents and analyzers; and cell culture media supplements for biopharmaceutical manufacturing. Becton, Dickinson & Co. was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.
Sector: Health Technology Medical Specialties

Dividend income advisory for BDX
Dividend Yield for BDX
The expected yield for BDX is 1.35 %, which can be considered at the lower side, after taxation the dividend will return barely more than inflation.

How is BDX priced
BDX has a trailing price to earnings ratio (P/E) of 65.14. The ratio is determined by the performance in the last 12 months. The P/E of BDX is at the high side, this mostly means the asset is valued to account for future revenue of profits of Becton, Dickinson & Co..

Debt to equity of BDX
With the Debt To Equity rate of BDX (1.02) we can conclude that Becton, Dickinson & Co. has more external liabilities than equity provided by shareholders. The company is leveraging it's investments with external cash. This can result in more returns but comes at a higher risk.

Price Prediction for BDX
On average analists predict that BDX will be correctly priced after a 16%. change. We can expect some long term capital gains.

Upcoming Dividends for BDX
Declared Ex Dividend Date Payment Date Record Date Amount Frequency
2019-04-29 2019-06-06 2019-06-28 2019-06-07 0.77 USD Quarterly

Dividends in past 12 months BDX
Declared Ex Dividend Date Payment Date Record Date Amount Frequency
2019-01-21 2019-03-07 2019-03-29 2019-03-08 0.77 USD Quarterly
2018-11-19 2018-12-07 2018-12-31 2018-12-10 0.77 USD Quarterly
2018-07-24 2018-09-06 2018-09-28 2018-09-07 0.75 USD Quarterly
2018-04-23 2018-06-07 2018-06-29 2018-06-08 0.75 USD Quarterly

Historical Dividends & Cap Growth for BDX
Past 5 Year Capital Gains 62 %
Dividend yield 9.88 %
Growth including dividends 71.89%
Latest news for BDX

2019-05-14 Disney, 21st Century Fox, Village Farms: 'Mad Money' Lightning Round Jim Cramer takes a closer look at Disney, 21st Century Fox, Village Farms, SailPoint Technologies, Magellan Midstream Partners, Becton Dickinson, Puma Biotechnology, Parsons and more….VFF
Original Article @ The Street

2019-05-13 Barclays Upgrades Becton Dickinson, Says Market Overreacted To FDA's Drug-Coated Balloon Update Becton Dickinson and Co’s (NYSE: BDX ) stock has lost more than 10 percent since March 15 in response to the FDA update on drug-coated balloons, or DCBs. The market seems to have overreacted to the news, and the upcoming FDA Advisory Committee meeting scheduled for June 19-20 may ease concerns, according to Barclays. The Analyst Kristen Stewart upgraded Becton Dickinson from Equal Weight to Overweight with an unchanged $266 price target. The Thesis Becton Dickinson gained the Lutonix DCB business when it acquired CR Bard in 2018. DCBs represented an estimated $200 million in sales and were among the company’s faster-growing … Full story available on
Original Article @ Benzinga

2019-05-09 Becton Dickinson and Co (BDX) CEO Vince Forlenza on Q2 2019 Results - Earnings Call Transcript No summary available.
Original Article @ Seeking Alpha

2019-05-09 Becton Dickinson & Co. (BDX) Q2 2019 Earnings Call Transcript BDX earnings call for the period ending March 31, 2019.
Original Article @ The Motley Fool

2019-05-09 Becton Dickinson's stock drops after profit, revenue growth outlook cut Shares of Becton Dickinson & Co. dropped 3.1% in morning trade Thursday, after the medical technology company topped fiscal second-quarter profit…
Original Article @ MarketWatch

2019-05-09 Becton Dickinson (BDX) Q2 Earnings Beat Estimates Becton Dickinson (BDX) delivered earnings and revenue surprises of 0.78% and -0.98%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Original Article @ Zacks Investment Research

2019-05-09 Becton Dickinson Earnings Beat, Revenue Misses In Q2 Becton Dickinson Earnings Beat, Revenue Misses In Q2
Original Article @

2019-05-08 Velano Primes for Growth with Funding from Intermountain Healthcare and Notable Individual Investors to Transform Blood Collection Globally SAN FRANCISCO, May 08, 2019 (GLOBE NEWSWIRE) -- Vascular access technology pioneer Velano Vascular today announced that it has secured $10 million as the initial tranche of a growth financing to fuel commercialization and the launch of additional novel vascular access solutions. This initial investment includes participation from strategic investor Intermountain Healthcare following the system's rollout of the PIVO™ needle-free blood collection technology; Becton Dickinson's former Chairman and CEO Edward Ludwig; notable entrepreneur, investor and health sector philanthropist Marc Benioff; Baxter International's former Chairman and CEO Robert Parkinson; Kapor Capital; and other undisclosed investors. Intermountain previously collaborated with San Francisco-based Velano Vascular to test, refine and pilot the company's needle free PIVO technology. Following hundreds of thousands of successful blood draws, Intermountain was the first health system in the United States to deploy PIVO systemwide as a standard of care. "As the first health system in the U.S. to bring PIVO to our inpatient populations, we have witnessed the many positive impacts of Velano's vision for a one-stick hospitalization firsthand," said Intermountain Healthcare President & Chief Executive Officer A.
Original Article @ Benzinga

2019-05-02 Analysts Estimate Becton Dickinson (BDX) to Report a Decline in Earnings: What to Look Out for Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Original Article @ Zacks Investment Research

2019-03-18 Becton Dickinson: Can This Stock Double Again? No summary available.
Original Article @ Seeking Alpha

Dividend Stats For BDX

  • Current Dividend Yield 1.35%
  • Past Year Payout: 3.04 USD
  • Next Ex Dividend 2019-06-06
  • Next Payment: 0.77 USD
  • Our score 61 %

Related dividend stocks